EMEA-000720-PIP01-09-M02
Key facts
| Invented name |
Xagrid
|
| Active substance |
Anagrelide
|
| Therapeutic area |
Haematology-Hemostaseology
|
| Decision number |
P/0325/2013
|
| PIP number |
EMEA-000720-PIP01-09-M02
|
| Pharmaceutical form(s) |
Capsule, hard
|
| Condition(s) / indication(s) |
Treatment of essential thrombocythaemia
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Takeda Pharmaceuticals International AG Ireland Branch
E-mail: medinfoemea@takeda.com |
| Decision type |
PM: decision on the application for modification of an agreed PIP
|
| Compliance procedure number |
EMEA-C-000720-PIP01-09-M02
|
| Compliance opinion date |
14/02/2014
|
| Compliance outcome |
positive
|